How to Get Your Insurance to Cover GLP-1 Medications

Understanding Why GLP-1s Are Often Denied

GLP-1 medications like Wegovy, Ozempic, and Zepbound carry list prices exceeding $1,000 per month, making them among the most expensive medications on the market. Insurance companies respond to this cost by aggressively restricting coverage through formulary exclusions, step therapy requirements, and strict prior authorization criteria. Understanding the financial logic behind these decisions is the first step toward overcoming them.

A major driver of denials is how insurers classify the indication. Many plans categorize GLP-1 medications prescribed for weight management as “lifestyle drugs,” a designation historically associated with cosmetic treatments and explicitly excluded from coverage under plan documents. This classification ignores the robust clinical evidence that obesity is a chronic disease with serious metabolic consequences, but it remains a powerful tool insurers use to deny claims without having to justify a medical determination.

Another common denial reason is that the prescribing diagnosis does not align with the plan's covered indications. For example, a plan may cover semaglutide for type 2 diabetes (Ozempic) but explicitly exclude it for obesity (Wegovy), even though the medications share the same active ingredient. If your doctor prescribes Wegovy and your plan does not cover weight management GLP-1s, you will receive a denial regardless of your medical need. Knowing this distinction upfront helps you and your doctor frame the prescription strategically.

Employer-sponsored self-funded plans present a separate challenge. Because self-funded plans are governed by ERISA rather than state insurance law, they are not subject to state benefit mandates. This means that even if your state requires coverage of obesity treatment, your employer's self-funded plan may be exempt. Confirming whether your plan is fully insured or self-funded is an important early step that will shape your appeals strategy.

Know Your Plan's Coverage Rules

Before you can fight a denial, you need to understand exactly what your plan says about GLP-1 medications. Start by requesting a copy of your Summary Plan Description (SPD) and the full plan document from your employer's HR department or your insurer's member portal. Look specifically for the pharmacy formulary, the exclusions section, and any clinical coverage criteria documents referenced in the formulary. These documents are legally required to be available to you and provide the written basis for any coverage decision.

Once you have the formulary, locate your specific medication by name and by generic name. Note which tier it sits on, whether prior authorization is required, and whether any quantity limits apply. If the drug is excluded entirely, the exclusion language will usually specify whether it applies to a drug class (e.g., “anti-obesity agents”) or to a specific indication. An exclusion by indication may leave room for coverage if your doctor can document a separate covered diagnosis, such as cardiovascular risk reduction or type 2 diabetes.

Call the member services number on the back of your insurance card and ask specifically: “What are the prior authorization criteria for [drug name] under my plan?” Request that the criteria be sent to you in writing. Ask whether step therapy is required (meaning you must try and fail other medications before your plan will authorize the GLP-1). Document the name of every representative you speak with, the date and time, and a summary of what was said. This log will be invaluable if you need to escalate.

The Prior Authorization Process Explained

Prior authorization (PA) is the process by which your insurance company reviews a prescription before agreeing to cover it. For GLP-1 medications, PA is nearly universal. The insurer will set out a list of clinical criteria your situation must meet before coverage is granted. Common criteria include a BMI at or above a specified threshold, documentation of a weight-related comorbidity, evidence that you have attempted other weight loss interventions, and sometimes a requirement that you be enrolled in a lifestyle modification program.

The PA request is typically submitted by your prescribing physician or their office staff, not directly by you. However, your involvement is critical. You should proactively ask your doctor “Has the PA been submitted?” and “What was the outcome?” rather than waiting to hear from the pharmacy. Delays in submitting or following up on a PA can extend the time you spend without medication by weeks. Confirm with both the doctor's office and your insurer that the submission was received.

Under the Affordable Care Act, non-urgent prior authorization decisions must be made within 72 hours for ongoing care and within 24 hours for urgent situations. If you have been waiting longer than these timeframes, you can contact your insurer's member services line to request a status update and flag the delay. Some states have enacted additional PA reform laws with stricter timelines, so it is worth checking your state's insurance department website for applicable rules.

How Your Doctor Can Help

Your physician is your most powerful ally in the insurance coverage process. A well-documented letter of medical necessity from your doctor can transform a denial into an approval. Ask your doctor to write a detailed letter that includes your current BMI and weight history, all weight-related diagnoses (including cardiovascular risk factors, prediabetes, hypertension, dyslipidemia, and sleep apnea), documentation of prior weight loss attempts and their outcomes, and a clear statement of why the specific GLP-1 medication is medically necessary for you in particular.

Ask your doctor to use the exact language from your plan's prior authorization criteria when writing the letter. If the criteria require a BMI of 30 or greater with one comorbidity, the letter should explicitly state that you meet both conditions. If the criteria require a documented failed attempt at lifestyle modification, your doctor should reference specific timeframes and interventions. This precision signals to the insurer's reviewer that the request has been carefully prepared and that denial will likely be challenged.

If your doctor is reluctant to engage with the PA process or appears unfamiliar with it, consider asking for a referral to a bariatric medicine specialist or an obesity medicine physician who regularly prescribes GLP-1 medications and has experience with insurance documentation. Specialists in this area are often more fluent in crafting the clinical arguments insurers require and may have existing relationships with insurers' medical review departments.

Writing a Strong Appeal Letter

When a PA is denied, you have the right to appeal. Federal law guarantees you both an internal appeal (reviewed by the insurer) and, if that fails, an external appeal (reviewed by an independent organization). Your denial letter will specify the deadline for filing an internal appeal, which is typically 180 days from the date of the denial notice. Do not miss this deadline.

Your appeal letter should be organized, professional, and heavily documented. Open with a brief statement of what you are appealing and why you believe the denial was incorrect. Cite the specific denial reason given in the denial letter, then methodically address each stated reason with counter-evidence. Include peer-reviewed clinical studies supporting the medical necessity of the medication, your doctor's letter of medical necessity, your complete medical records documenting your weight history and comorbidities, and documentation of any prior treatment attempts.

Reference your plan's own coverage documents in your appeal. If the plan covers treatment of obesity as a disease elsewhere in the document, point to that language. If the denial is based on an exclusion for “lifestyle drugs” but your drug is also indicated for a covered condition (such as cardiovascular risk reduction in the case of Wegovy), argue that the exclusion does not apply. Patient advocacy organizations such as the Obesity Action Coalition (OAC) offer free appeal letter templates and resources that can serve as a strong starting point.

Send your appeal by certified mail or a trackable method and keep copies of everything. Follow up within five business days to confirm receipt. If you do not receive a decision within the federally mandated timeframe (typically 30 days for standard internal appeals), escalate immediately. A failure to issue a timely decision may itself be an independent ground for a complaint to your state insurance commissioner.

Using the Cardiovascular Approval to Your Advantage

In March 2024, the FDA approved a new indication for Wegovy (semaglutide 2.4mg) specifically for reducing the risk of serious cardiovascular events—heart attack, stroke, and cardiovascular death—in adults with established cardiovascular disease and obesity or overweight. This landmark approval, based on the SELECT trial which enrolled over 17,500 patients, fundamentally changed the coverage calculus for many insurers.

If you have a history of heart attack, stroke, peripheral arterial disease, or another form of established cardiovascular disease, and you have a BMI of 27 or greater, you may now qualify for Wegovy under a cardiovascular indication rather than a weight management indication. This matters because many plans that exclude “anti-obesity agents” may nonetheless cover cardiovascular medications. Ask your doctor to document your cardiovascular diagnoses prominently in any PA submission and to explicitly cite the FDA cardiovascular indication when requesting coverage.

Even for plans that still deny coverage under the cardiovascular indication, the SELECT trial data strengthens your appeal significantly. You can cite the study results showing a 20% reduction in major adverse cardiovascular events, the cost-effectiveness literature comparing the cost of the medication to the cost of treating heart attacks and strokes, and the published guidelines from the American Heart Association and American College of Cardiology endorsing GLP-1 use in this population. These clinical references shift the burden of justification onto the insurer.

When to Escalate to Your State Insurance Commissioner

If your internal appeal is denied and your external appeal is also unsuccessful—or if your insurer fails to follow the required timelines and procedures—filing a complaint with your state's Department of Insurance (DOI) is a legitimate and often effective next step for fully insured plans. State insurance commissioners regulate insurer conduct and can compel insurers to reverse improper denials or comply with state benefit mandates. Some states, including Illinois, New York, and California, have enacted laws requiring insurers to cover obesity treatment, including GLP-1 medications meeting clinical criteria.

Filing a DOI complaint is free and relatively straightforward. Most state DOI websites have an online complaint portal. Your complaint should describe the coverage dispute, the decision you received, any appeals you filed, and the basis for your belief that the denial was improper. Attach copies of your denial letters, appeal letters, and your plan's coverage documents. Once filed, insurers are required to respond to the DOI within a specified period, and the DOI will issue a determination. Even if the DOI does not rule in your favor, the complaint creates a formal record and often prompts insurers to reconsider.

For self-funded employer plans governed by ERISA, state insurance commissioners have limited authority. However, you can contact your employer's HR or benefits department directly and escalate internally. Some employers have benefits advocacy hotlines or third-party administrators who can intervene. You may also consult an employee benefits attorney if the denied coverage is resulting in significant financial hardship. Patient advocacy organizations, including the OAC and STOP Obesity Alliance, can also provide guidance specific to your situation and state.